The US Food and Drug Administration (FDA) has approved an expanded indication for Thrombate III, the Grifols-developed drug treating a rare blood-clotting disorder. Thrombate III is used to prevent hereditary antithrombin deficiency (hATd), becoming the only antithrombin concentrate (ATc) to be approved in both adult and paediatric patients. The decision… Read More
Positive results from a Phase II/III clinical trial evaluating Grifols’ intravenous immunoglobulin (IVIG) to treat patients with post-polio syndrome (PPS) have demonstrated a significant improvement in distance walked compared to placebo. The immunomodulatory properties of IVIG – in this case Flebogamma 5% DIF (immune globulin intravenous [human])… Read More
Grifols has finished recruiting the second cohort of its Phase I/II study evaluating two different doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%) as a subcutaneous (SC) option for the treatment of alpha1-antitrypsin (AAT) deficiency. Cohort 2 patients will receive a 180mg/kg dose of SC Alpha-1… Read More
Grifols and biotechnology startup, FcR Therapeutics, have agreed to collaborate on recombinant nanobodies to treat autoimmune diseases. The nanobodies, which are small highly specialised antibody fragments, would act to restrain or inhibit the activity of certain Fc receptors (FcR), naturally occurring proteins found on the surface of… Read More
